The collaboration will support the clinical development and manufacturing scale-up of Ferric Carboxymaltose injection to improve access to anaemia treatment.
Hyderabad: BE Biosol Private Limited, a wholly owned subsidiary of Biological E. Limited, has entered into an agreement with the Gates Foundation to expand access to Ferric Carboxymaltose (FCM) injection across multiple countries in Africa.
The partnership aims to address iron deficiency anaemia, which affects millions of people worldwide, particularly in low- and middle-income countries where access to affordable treatment remains a challenge.
Collaboration to Support Product Development and Manufacturing
Under the agreement, the Gates Foundation will support BE Biosol in scaling up manufacturing and advancing the clinical development of FCM injection for target markets. Meanwhile, BE Biosol will contribute its research and development capabilities and manufacturing infrastructure to the programme.
The company’s manufacturing facility in Shamirpet, Telangana, commissioned in 2018, has undergone inspections and received approvals from major regulatory agencies, including the US Food and Drug Administration (USFDA), Infarmed (Portugal), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Brazil’s ANVISA.
BE Biosol Eyes Global Market Opportunities
The collaboration also aligns with BE Biosol’s plans to strengthen its presence in international markets as the US and European Ferric Carboxymaltose markets move towards generic competition.
By leveraging its manufacturing capabilities and proprietary active pharmaceutical ingredient (API) technology, the company aims to develop a cost-competitive product offering for global markets.
Commenting on the partnership, Narender Mantena, Managing Director of BE Biosol Private Limited, said the collaboration reflects the Gates Foundation’s confidence in the company’s ability to develop and manufacture complex sterile formulations at competitive costs and scale. He added that the partnership supports BE Biosol’s ambition to build a globally competitive contract development and manufacturing organisation (CDMO) platform.
As per a company press release, the collaboration will support the development, manufacturing scale-up and wider availability of Ferric Carboxymaltose injection, with the aim of improving access to iron deficiency anaemia treatment in Africa.



















